Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Hypomethylating agents (HMAs) are widely used in the treatment of myelodysplastic syndromes (MDSs), yet identifying those patients unlikely to benefit remains challenging. We assessed response and overall survival (OS) in 247 patients molecularly profiled by next-generation sequencing (NGS) before f...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood Adv
Main Authors: Hunter, Anthony M., Komrokji, Rami S., Yun, Seongseok, Al Ali, Najla, Chan, Onyee, Song, Jinming, Hussaini, Mohammad, Talati, Chetasi, Sweet, Kendra L., Lancet, Jeffrey E., Padron, Eric, List, Alan F., Sallman, David A.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2021
Fag:
Myeloid Neoplasia
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7903224/
https://ncbi.nlm.nih.gov/pubmed/33591325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003508
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker